EGFR inhibitors such as erlotinib, lapatinib, and cetuximab alone or in combination with sorafenib have been tested for HCC treatment [61], but did not provide additional benefit to these patients [62]. This evidence concerns the gene EGFR and hepatocellular carcinoma.